Misra Monika
Department of Pharmacology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, 202002, India.
Curr Cardiol Rev. 2013 Feb 1;9(1):33-54. doi: 10.2174/157340313805076322.
The rising tide of obesity and its related disorders is one of the most pressing health concerns worldwide, yet existing medicines to combat the problem are disappointingly limited in number and effectiveness. Recent advances in mechanistic insights into the neuroendocrine regulation of body weight have revealed an expanding list of molecular targets for novel, rationally designed antiobesity pharmaceutical agents. Antiobesity drugs act via any of four mechanisms: 1) decreasing energy intake, 2) increasing energy expenditure or modulating lipid metabolism, 3) modulating fat stores or adipocyte differentiation, and 4) mimicking caloric restriction. Various novel drug candidates and targets directed against obesity are currently being explored. A few of them are also in the later phases of clinical trials. This review discusses the development of novel antiobesity drugs based on current understanding of energy homeostasis.
肥胖及其相关疾病的不断增加是全球最紧迫的健康问题之一,然而用于解决这一问题的现有药物在数量和有效性方面却令人失望地有限。近年来,对体重神经内分泌调节机制的深入了解揭示了越来越多可供合理设计新型抗肥胖药物的分子靶点。抗肥胖药物通过以下四种机制之一发挥作用:1)减少能量摄入;2)增加能量消耗或调节脂质代谢;3)调节脂肪储存或脂肪细胞分化;4)模拟热量限制。目前正在探索各种针对肥胖的新型候选药物和靶点。其中一些也正处于临床试验的后期阶段。本综述基于对能量稳态的当前理解,讨论新型抗肥胖药物的研发情况。